EVOGENE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 234.8 ILa | -2.61% |
|
-15.02% | -21.68% |
| Apr. 02 | Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd | CI |
| Mar. 20 | Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq | MT |
| Sales 2024 * | 17M 6.4B | Sales 2025 * | 31.5M 11.85B | Capitalization | 31.59M 11.89B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -7.53B | Net income 2025 * | -17M -6.4B | EV / Sales 2024 * | 1.86 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | -2.61% | ||
| 1 week | -15.02% | ||
| Current month | -16.62% | ||
| 1 month | -19.15% | ||
| 3 months | -24.79% | ||
| 6 months | +19.73% | ||
| Current year | -21.68% |
1 week
231.20
264.20
1 month
231.20295.00
Current year
231.20370.00
1 year
189.30610.40
3 years
189.301 560.00
5 years
189.303 350.00
10 years
189.306 344.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-21 | 234.8 | -2.61% | 83,238 |
| 24-04-18 | 241.1 | -7.16% | 103,992 |
| 24-04-17 | 259.7 | -0.50% | 54,087 |
| 24-04-16 | 261 | -5.54% | 86,449 |
| 24-04-15 | 276.3 | -0.47% | 31,259 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 21, 2024 at 08:49 am EDT
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-05-27
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.68% | 31.48M | |
| -0.02% | 42.11B | |
| +45.83% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- EVGN Stock
